Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Howdy Phantom, Please don't spend time doing research on this question, I'm not looking for an exact answer, just looking for your general opinion which I know from reading your posts for years you already have this info pretty close in your head.
In the past, when I questioned why a psoriasis company was worth so much more than a AML cancer company in roughly the same stage of development ... your lesson was ... SIZE OF THE MARKET .... which of course makes sense.
So, my question (or actually two part questions) is/are this:
IF AML market size is a 1 and psoriasis market size is a 10, can you give a rough estimate of what number the lymphoma market size would be?
Also, same question for pancreatic market?
This is the part two part: You have said many times in the past that AML Active was difficult indication to go after ... and you have said that pancreatic was also a difficult indication to go after, so, based on your number for the pancreatic market from the above question, and based on the Difficulty of pancreatic, do you think (even if they somehow are successful) that it is worth spending more money on pancreatic when AML Adjuvant and Lymphoma are futher along and may be a better market size?
I guess I can sum it up by asking, is MRKR trying to make money (profits) or are they trying to be altruistic even if the market size (and potential profits) are small?
Thank You